hotspot -WSS

hotspot

author：focus 2025-09-30 18:59:06 - browse：73252

At some point this summer, the drugmaker Novo Nordisk will release results from a closely watched study that, if successful, could further uncork demand for new obesity medications, streamline insurance coverage for the therapies, and demonstrate long-lasting health benefits.

The Select trial, as the study is called, is the first large, randomized trial to test whether long-term treatment with a weight loss drug can meaningfully improve patients’ cardiovascular health. Novo is testing Wegovy, a weekly injection also sold under the brand name Ozempic for type 2 diabetes, against placebo in the five-year study.

The implications are massive, and not just for Novo. Wegovy is part of a class of medicines that target a hormone called GLP-1, which curbs patients’ appetites. Those drugs have demonstrated an ability to help people lose dramatic amounts of weight in clinical trials, but payers, including Medicare, have been slow to reimburse for them without definitive data on their long-term health benefits.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Malaria cases in Florida and Texas: Here’s what you need to know
Next article： Readout Newsletter: Merck, J&J, and long Covid

Wikipedia

focus

WSS

How digital therapeutics firms are pivoting after Pear's bankruptcy

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

FDA approves world's first CRISPR

STAT letters to the editor on burnt

What PEPFAR has meant on the ground in Ukraine

focus

hotspot

focus

Affirmative action in medical school literally saved lives

Sanofi says it has 12 blockbusters on the way. Will investors believe it?

The high cost of giving birth even with insurance

Prior authorization will have to move faster under new Biden rule

Supreme Court strikes down use of affirmative action

Prior authorization will have to move faster under new Biden rule

Guidelines to prevent youth baseball injuries need more muscle

Prior authorization will have to move faster under new Biden rule

Trump demands the U.S. pay no more for drugs than other countries … again

CMS should re

entertainment

After sickle

Dewpoint Therapeutics lays off staff after losing partnerships

Americans' trust in science, scientist continues decline: Report

Americans' trust in science, scientist continues decline: Report

NIH director takes cautious approach to Biden drug pricing priority

My yearlong odyssey to get my son’s ADHD medication covered

Wikipedia

hotspot

focus

Wikipedia